- In January 2025, Novo Nordisk announced the launch of its next-generation smart insulin pen, the NovoPen 7, in the European Union. The NovoPen 7 features advanced connectivity for seamless integration with diabetes management apps, allowing users to track their insulin doses, monitor blood glucose levels, and optimize their insulin therapy. It also includes a memory function and Bluetooth capability for real-time data sharing, enhancing patient compliance and outcomes
- In October 2024, Eli Lilly and Company presented its latest innovation, the Tempo Pen®, at the European Association for the Study of Diabetes (EASD) 2024 meeting. The Tempo Pen® is designed to improve patient experience with intuitive handling, accurate dosing, and smart connectivity, helping diabetes patients achieve better glycemic control
- In September 2024, Biocon Biologics, a subsidiary of Biocon, showcased its advanced insulin pen portfolio, including the Basalog One, at the World Diabetes Congress in Barcelona. These pens are designed for ease of use, precise dosing, and enhanced patient comfort, reflecting the company's commitment to affordable and innovative diabetes care solutions
- In September 2024, Owen Mumford launched the Aidaptus auto-injector, a next-generation pen system for diabetes and chronic disease management. The device offers customizable dose delivery, ergonomic design, and compatibility with a wide range of drug formulations, making it an ideal solution for diabetes patients requiring regular insulin therapy
